Serum Amylase and Isoamylase in Chronic Renal Failure

Mt, Bardella; Ml, Bianchi; Molteni, N; Garbín, Cléa Adas Saliba; Valenti, G; Buccianti, G.; Pa, Bianchi

doi:10.1177/039139888701000409

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distribution of pancreatic isoenzymes was within normal limits in 34 of 37 patients and only slightly altered in 3. Seventeen of the patients were on conservative treatment, 10 on hemodialysis, and 10 on continuous ambulatory peritoneal dialysis (CAPD); no significant differences in serum amylase levels were detected among the three subgroups (48) nor between the two modalities in another study (49). Vaziri et al (50) reported that elevation of the plasma isoenzyme P3 was a reliable indicator of pancreatitis in dialysis patients, suggesting some uncertainty in this area.…”

Section: Pancreatic Markers and Liver Function Testsmentioning

confidence: 99%

Reviews: Altered Laboratory Findings Associated with End‐Stage Renal Disease

Robitaille¹,

Lafrance

Leblanc

2006

Seminars in Dialysis

View full text Add to dashboard Cite

Several laboratory parameters can be altered in advanced renal failure. Results may be difficult to interpret and may become misleading and unreliable in such a context. On the other hand, some of the alterations may reflect real abnormalities. Thus sufficient knowledge and careful judgment are required by the clinician. We reviewed different publications related to biochemical anomalies in renal failure and report some of the main findings. The sections are divided as follows: cardiovascular risk factors and markers, inflammation markers, pancreatic and liver function tests, hormones, bone turnover indices and parathyroid hormone assays, tumor markers, carbohydrate metabolism indicators, and others. The information provided should be useful to clinicians involved in the care of renal failure patients.

show abstract

Section: Pancreatic Markers and Liver Function Testsmentioning

confidence: 99%

Reviews: Altered Laboratory Findings Associated with End‐Stage Renal Disease

Robitaille¹,

Lafrance

Leblanc

2006

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

Pancreatitis in children on chronic dialysis treated with valproic acid

1990

View full text Add to dashboard Cite

Four children treated with maintenance dialysis, three peritoneal and one hemodialysis, developed pancreatitis while receiving valproic acid (VPA) for chronic seizure disorders. Two patients recovered, eventually resuming VPA therapy after successful cadaveric renal transplantation. Two children died after complications of pancreatitis. No episodes of pancreatitis occurred in the other 74 children in this maintenance dialysis population; none of whom received VPA. Although pancreatitis is a known complication of VPA treatment or end-stage renal disease (ESRD), this is the first reported series specifically relating pancreatitis to VPA administration in children treated with maintenance dialysis. The literature related to the association of pancreatitis with VPA administration and ESRD therapy is briefly reviewed and the clinical implications are discussed.

show abstract

CAPD and Pancreatitis: No Connection

Gupta¹,

Zheng²,

Balaskas³

et al. 1992

Perit Dial Int

View full text Add to dashboard Cite

Autopsy studies have shown that approximately 56% of patients on long-term continuous ambulatory peritoneal dialysis (CAPD) develop various pancreatic abnormalities, such as acute and chronic pancreatitis, fibrosis, and acinar dilatation. This prevalence of anatomical abnormalities is similar to that observed in patients on hemodialysis and higher than that in those with normal renal function. However, clinical acute pancreatitis is an uncommon complication of CAPD (0.9%), and this prevalence is similar to that (1.7%) of patient son hemodialysis. We can attribute acute pancreatitis in CAPD patients to no single factor. Perhaps preexisting anatomical abnormalities of the pancreas make the CAPD patient susceptible to acute pancreatitis when exposed to a variety of physiological and non physiological influences. The diagnosis of acute pancreatitis in CAPD patients is difficult, because symptoms and signs are similar to those of dialysis-associated peritonitis. Serum amylase values three times greater than the upper limit of normal and effluent amylase greater than 100 U/L suggest the diagnosis of acute pancreatitis. Serum lipase, isoamylase, and pancreatic secretory trypsin inhibitor are not helpful. In confirming the diagnosis, a computed tomography (CT) scan is more helpful than ultrasound, although it is positive in only 50–60% of cases. One should harbor a high index of suspicion concerning acute pancreatitis if a CAPD patient presenting with suspected peritonitis has either a negative effluent culture or does not respond to antibiotic therapy.

show abstract

Serum Amylase and Isoamylase in Chronic Renal Failure

Cited by 3 publications

References 16 publications

Reviews: Altered Laboratory Findings Associated with End‐Stage Renal Disease

Reviews: Altered Laboratory Findings Associated with End‐Stage Renal Disease

Pancreatitis in children on chronic dialysis treated with valproic acid

CAPD and Pancreatitis: No Connection

Contact Info

Product

Resources

About